查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830995

色素减退症治疗市场

Hypopigmentation Disorder Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

色素减退症治疗市场预计将从 2024 年的 47 亿美元增加到 2031 年的 67 亿美元，2025 年至 2031 年的复合年增长率预计为 5.41%。

市场洞察与分析师观点：色素减退症可能发展为色素脱失症，其特征是皮肤色素水平欠佳，这与色素完全丧失导致的脱色症不同。推动色素减退症治疗市场成长的关键因素包括人们对色素减退症认识的提高、美容治疗技术的进步以及老龄化人口的稳定增长。此外，白化病、色素减退后和白斑症等色素减退相关疾病的发生率上升预计将在未来几年推动色素减退症治疗市场的发展。此外，消费者对皮肤健康的投入不断增长以及对治疗方案的认识不断提高，预计很快就会对该市场产生积极影响。天然和植物成分的出现可能会影响色素减退症治疗市场的趋势，因为这些产品对于满足全球药妆需求至关重要。相反，美容治疗和手术的高昂成本对市场成长构成了挑战。

根据美国国家临床试验 (NCT) 註册中心的数据，Incyte 公司于 2020 年 6 月启动了一项 II 期临床试验，以评估鲁索利替尼在美国治疗白斑症的安全性和有效性。因此，与色素减退症相关的临床试验数量的增加是支持市场成长的另一个重要因素。

成长动力与挑战：色素减退症发生率上升推动市场扩张。白色糠疹、白斑症、白化症和发炎后色素减退是与色素减退症相关的关键疾病。白癜风是一种全球公认的疾病。 2023年12月发表在《皮肤病学实用与概念》上的一项研究表明，白斑症是一种常见的皮肤病，男女均可发病，但女性发病率更高，超过60%的患者在30岁之前发病。白斑症发病率和盛行率的上升预计将进一步推动色素减退治疗的需求。

扎加齐格大学医学杂誌 2023 年 3 月的一篇文章指出，色素减退症是儿童常见的一类皮肤病，其盛行率在不同国家有所不同，从 3.6% 到 9.9% 不等。此外，微创手术的兴起也极大地促进了色素减退症的普及，因为这些手术需要更短的住院时间，从而减轻了疼痛并减少了併发症。根据美国整形外科医师协会 (ASPS) 的数据，自 2000 年以来，美国实施的微创美容手术数量增加了近 200%。因此，对微创美容手术日益增长的偏好进一步推动了色素减退症治疗市场的成长。然而，白斑症和白化病等疾病的光疗法费用高昂，而白斑症手术治疗费用昂贵，限制了这些疗法的普及，从而限制了色素减退症治疗市场的成长。

策略洞察报告细分与范围：色素减退症治疗市场分析透过考察以下细分市场进行：治疗类型、疾病指征和最终用户。色素减退症治疗市场报告的地理范围包括北美（美国、加拿大和墨西哥）、欧洲（英国、德国、法国、义大利、西班牙和欧洲其他地区）、亚太地区（中国、日本、印度、澳洲、韩国和亚太其他地区）、中东和非洲（阿联酋、沙乌地阿拉伯、南非和中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲（巴西、阿根廷和南美洲和其他地区中美洲）。

細項分析：基于治疗的洞察：依治疗类型，市场分为外用药物、雷射疗法、化学换肤、微晶磨皮、光疗等。外用药物在2023年占据色素减退症治疗市场的最大份额，预计在2023年至2031年期间将呈现最高的复合年增长率。

基于疾病适应症的洞见：就疾病适应症而言，色素减退症治疗市场分为白色糠疹、白化病、白斑症、发炎后色素减退症及其他。白斑症细分市场在2023年占据了相当大的市场份额，预计在2023年至2031年期间将实现最高的复合年增长率。

基于终端用户的洞察：就终端用户而言，市场细分为美容诊所、皮肤科中心和医院。美容诊所在2023年占据了色素减退症治疗市场的最大份额，预计在2023年至2031年的预测期内将实现最高的复合年增长率。

色素减退症治疗市场报告范围区域分析：2023 年，北美占据色素减退症治疗市场的最大份额，预计在整个预测期内将保持领先地位。美国主导该地区和全球市场。完善的医疗保健基础设施、日益​​增强的皮肤健康意识、色素减退相关疾病的患病率上升以及大量为炎症后色素沉着患者提供有吸引力的治疗选择的公司的存在等因素是北美市场增长的主要驱动力。此外，亚洲人日益增长的美容意识和不断提高的美容标准，加上大量公司进入市场和老牌企业的持续成长，都是亚太地区色素减退症治疗市场扩张的重要因素。

竞争格局与重点公司：色素减退症治疗市场的预测可以帮助利害关係人制定成长策略。色素减退症治疗市场报告中介绍的重点公司包括艾尔建 (Allergan)、修丽可 (SkinCeuticals)、皮尔法伯集团 (Pierre Fabre Group)、因塞特 (Incyte Corporation)、Episciences Inc.、Phio Pharmaceuticals、欧邦琪 (Obagi Cosmeceticals LLC)、Alvo、Abbpora、Abbuora、Abbus LLC。这些公司专注于扩大产品供应，以满足全球日益增长的消费者需求，并利用其全球影响力服务广泛的客户群。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：色素减退症治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：色素减退症治疗市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：色素减退症治疗市场－全球市场分析

  • 色素减退症治疗－全球市场概览
  • 色素减退症治疗－全球市场及2031年预测

第七章：色素减退症治疗市场－收入分析－依治疗类型，2021-2031

  • 概述
  • 外用药物
  • 雷射治疗
  • 化学换肤
  • 微晶磨皮
  • 光疗
  • 皮肤移植
  • 色素细胞移植
  • 其他的

第 8 章：色素减退症治疗市场 - 收入分析 - 按疾病适应症，2021-2031 年

  • 概述
  • 白斑
  • 白化病
  • 色素减退/脱色疤痕
  • 黄褐斑
  • 发炎后色素减退（PIH）
  • 其他的

第九章：色素减退症治疗市场-收入分析-按最终用户，2021-2031

  • 概述
  • 医院
  • 美容诊所
  • 皮肤科中心
  • 其他的

第 10 章：色素减退症治疗市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 13 章：色素减退症治疗市场 - 关键公司简介

  • Allergan
  • SkinCeuticals
  • Pierre Fabre
  • Episciences, Inc
  • RXi Pharmaceuticals Corporation
  • Obagi Cosmeceuticals LLC
  • Incyte
  • L’oreal Paris
  • CLINUVEL PHARMACEUTICALS LTD
  • STRATA Skin Sciences
  • TeVido BioDevices, Inc.
  • Courage + Khazaka electronic GmbH
  • AVITA Medical
  • Galderma S.A.
  • Vital Esthetique

第 14 章：附录

简介目录
Product Code: TIPRE00004312

The hypopigmentation disorder treatment market is projected to increase from US$ 4.7 billion in 2024 to US$ 6.7 billion by 2031, with an estimated CAGR of 5.41% from 2025 to 2031.

Market Insights and Analyst View:Hypopigmentation disorders can progress into depigmentation disorders, characterized by suboptimal skin pigment levels, unlike depigmentation conditions which result from the total loss of pigments. Key factors propelling the growth of the hypopigmentation disorder treatment market include heightened awareness of hypopigmentation disorders, advancements in aesthetic treatment technologies, and a steady increase in the aging population. Additionally, the rising incidence of hypopigmentation-related disorders such as albinism, post-hypopigmentation, and vitiligo is expected to drive the market for hypopigmentation disorder treatments in the upcoming years. Furthermore, the growing consumer investment in skin health and awareness of treatment options is anticipated to positively impact this market soon. The emergence of natural and plant-based ingredients is likely to shape trends in the hypopigmentation disorder treatment market, as these products have been essential in fulfilling the global demand for cosmeceuticals. Conversely, the high costs associated with cosmetic treatments and surgeries pose a challenge to market growth.

As per the National Clinical Trials (NCT) registry, Incyte Corporation initiated a phase II clinical trial in June 2020 to assess the safety and efficacy of Ruxolitinib for treating vitiligo in participants in the US. Thus, the increasing number of clinical trials related to hypopigmentation disorders is another significant factor supporting market growth.

Growth Drivers and Challenges:Rising Incidence of Hypopigmentary Disorders Fuels Market Expansion

Pityriasis alba, vitiligo, albinism, and post-inflammatory hypopigmentation are key conditions linked to hypopigmentation disorders. Vitiligo is a widely recognized condition globally. A study published in Dermatology Practical and Conceptual in December 2023 indicates that vitiligo is a common skin condition affecting both genders, though it is more prevalent in females, with over 60% of patients experiencing onset before the age of 30. The increasing incidence and prevalence of vitiligo are expected to further drive the demand for hypopigmentation treatments.

An article in the Zagazig University Medical Journal from March 2023 notes that hypopigmentation disorders are a frequent group of dermatoses in pediatric populations, with prevalence rates varying by country, ranging from 3.6% to 9.9%. Moreover, the rise of minimally invasive procedures, which require shorter hospital stays and result in less pain and fewer complications, has significantly contributed to their growing popularity. According to the American Society of Plastic Surgeons (ASPS), the number of minimally invasive cosmetic procedures performed in the US has increased by nearly 200% since 2000. Thus, the growing preference for minimally invasive cosmetic procedures is further driving the growth of the hypopigmentation disorder treatment market. However, the high costs associated with light therapy for conditions like vitiligo and albinism, as well as the expensive nature of surgical treatments for vitiligo, limit their adoption and consequently restrict the growth of the hypopigmentation disorder treatment market.

Strategic Insights

Report Segmentation and Scope:The analysis of the hypopigmentation disorder treatment market has been conducted by examining the following segments: treatment type, disease indication, and end user. The geographic scope of the hypopigmentation disorder treatment market report includes North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:Treatment-Based Insights

By treatment type, the market is divided into topical drugs, laser therapy, chemical peels, microdermabrasion, phototherapy, and others. The topical drugs segment accounted for the largest share of the hypopigmentation disorder treatment market in 2023 and is expected to exhibit the highest CAGR during the period from 2023 to 2031.

Disease Indication-Based Insights

In terms of disease indication, the hypopigmentation disorder treatment market is categorized into pityriasis alba, albinism, vitiligo, post-inflammatory hypopigmentation, and others. The vitiligo segment held a substantial market share in 2023 and is projected to register the highest CAGR from 2023 to 2031.

End User-Based Insights

Regarding end users, the market is segmented into aesthetics clinics, dermatology centers, and hospitals. The aesthetics clinics segment represented the largest share of the hypopigmentation disorder treatment market in 2023 and is anticipated to achieve the highest CAGR during the forecast period from 2023 to 2031.

Hypopigmentation Disorder Treatment Market Report Scope

Regional Analysis:In 2023, North America held the largest share of the hypopigmentation disorder treatment market and is expected to maintain its leading position throughout the forecast period. The US dominates this region and the global market. Factors such as a well-established healthcare infrastructure, increasing awareness about skin health, rising prevalence of hypopigmentation-related diseases, and a significant presence of companies offering appealing treatment options for patients with post-inflammatory hyperpigmentation are key drivers of market growth in North America. Additionally, the growing beauty concerns and rising beauty standards among Asians, along with the influx of companies entering the market and the ongoing growth of established players, are significant contributors to the expansion of the hypopigmentation disorder treatment market in the Asia Pacific region.

Competitive Landscape and Key Companies:The forecast for the hypopigmentation disorder treatment market can assist stakeholders in devising their growth strategies. Key companies profiled in the hypopigmentation disorder treatment market report include Allergan, SkinCeuticals, Pierre Fabre Group, Incyte Corporation, Episciences Inc., Phio Pharmaceuticals, Obagi Cosmeceuticals LLC, Alvogen, Bella Aurora, and AbbVie. These companies are focused on expanding their product offerings to meet the increasing consumer demand globally, leveraging their global presence to serve a wide customer base.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Hypopigmentation Disorder Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Hypopigmentation Disorder Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Hypopigmentation Disorder Treatment Market - Global Market Analysis

  • 6.1 Hypopigmentation Disorder Treatment - Global Market Overview
  • 6.2 Hypopigmentation Disorder Treatment - Global Market and Forecast to 2031

7. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By Treatment, 2021-2031

  • 7.1 Overview
  • 7.2 Topical Drugs
  • 7.3 Laser Therapy
  • 7.4 Chemical Peels
  • 7.5 Microdermabrasion
  • 7.6 Phototherapy
  • 7.7 Skin Grafting
  • 7.8 Pigment cell transplantation
  • 7.9 Others

8. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By Disease Indication, 2021-2031

  • 8.1 Overview
  • 8.2 Vitiligo
  • 8.3 Albinism
  • 8.4 Hypopigmented/depigmented scars
  • 8.5 Melasma
  • 8.6 Post-Inflammatory Hypopigmentation (PIH)
  • 8.7 Others

9. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 9.1 Overview
  • 9.2 Hospitals
  • 9.3 Aesthetic Clinics
  • 9.4 Dermatology Centers
  • 9.5 Others

10. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Hypopigmentation Disorder Treatment Market Overview
    • 10.1.2 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts to 2031
    • 10.1.3 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Treatment
    • 10.1.4 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Disease Indication
    • 10.1.5 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By End User
    • 10.1.6 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Hypopigmentation Disorder Treatment Market
        • 10.1.6.1.1 United States Hypopigmentation Disorder Treatment Market, by Treatment
        • 10.1.6.1.2 United States Hypopigmentation Disorder Treatment Market, by Disease Indication
        • 10.1.6.1.3 United States Hypopigmentation Disorder Treatment Market, by End User
      • 10.1.6.2 Canada Hypopigmentation Disorder Treatment Market
        • 10.1.6.2.1 Canada Hypopigmentation Disorder Treatment Market, by Treatment
        • 10.1.6.2.2 Canada Hypopigmentation Disorder Treatment Market, by Disease Indication
        • 10.1.6.2.3 Canada Hypopigmentation Disorder Treatment Market, by End User
      • 10.1.6.3 Mexico Hypopigmentation Disorder Treatment Market
        • 10.1.6.3.1 Mexico Hypopigmentation Disorder Treatment Market, by Treatment
        • 10.1.6.3.2 Mexico Hypopigmentation Disorder Treatment Market, by Disease Indication
        • 10.1.6.3.3 Mexico Hypopigmentation Disorder Treatment Market, by End User
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Hypopigmentation Disorder Treatment Market - Key Company Profiles

  • 13.1 Allergan
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 SkinCeuticals
  • 13.3 Pierre Fabre
  • 13.4 Episciences, Inc
  • 13.5 RXi Pharmaceuticals Corporation
  • 13.6 Obagi Cosmeceuticals LLC
  • 13.7 Incyte
  • 13.8 L’oreal Paris
  • 13.9 CLINUVEL PHARMACEUTICALS LTD
  • 13.10 STRATA Skin Sciences
  • 13.11 TeVido BioDevices, Inc.
  • 13.12 Courage + Khazaka electronic GmbH
  • 13.13 AVITA Medical
  • 13.14 Galderma S.A.
  • 13.15 Vital Esthetique

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud